MAPT and Alzheimer disease: This study was limited by the absence of analysis of AD pathology, including Aβ and tau deposits, which have been demonstrated to affect cognitive decline and functional brain changes throughout the trajectory of AD (Canuet et al., 2015; Sperling et al., 2019).